MX2014010501A - Geles tópicos que contienen péptidos de alfa-conexina c- terminal (act). - Google Patents
Geles tópicos que contienen péptidos de alfa-conexina c- terminal (act).Info
- Publication number
- MX2014010501A MX2014010501A MX2014010501A MX2014010501A MX2014010501A MX 2014010501 A MX2014010501 A MX 2014010501A MX 2014010501 A MX2014010501 A MX 2014010501A MX 2014010501 A MX2014010501 A MX 2014010501A MX 2014010501 A MX2014010501 A MX 2014010501A
- Authority
- MX
- Mexico
- Prior art keywords
- act
- peptides
- alpha connexin
- terminal
- gels containing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Marine Sciences & Fisheries (AREA)
- Inorganic Chemistry (AREA)
- Cell Biology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Cosmetics (AREA)
Abstract
Preparación de un fármaco en forma de gel tópico que contiene una composición que comprende un polipéptido aislado que tiene una secuencia de aminoácidos carboxilo terminal de una alfa-conexina (péptido ACT), estabilizantes de péptidos, excipientes, agentes amortiguadores del pH y semejantes. Se divulgan la formulación y los pasos de preparación para la elaboración de un gel tópico estable, elegante y vertible. La formulación resultante presenta una estabilidad a largo plazo adecuada para aplicaciones estéticas y terapéuticas, inclusive para prevenir la formación de cicatrices y para acelerar la curación de heridas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261605528P | 2012-03-01 | 2012-03-01 | |
PCT/US2013/028727 WO2013131040A1 (en) | 2012-03-01 | 2013-03-01 | Topical gels containing alpha connexin c-terminal (act) peptides |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014010501A true MX2014010501A (es) | 2015-03-09 |
MX351881B MX351881B (es) | 2017-11-01 |
Family
ID=49083360
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014010501A MX351881B (es) | 2012-03-01 | 2013-03-01 | Geles tópicos que contienen péptidos de alfa-conexina c- terminal (act). |
Country Status (18)
Country | Link |
---|---|
US (5) | US8846605B2 (es) |
EP (1) | EP2819682B1 (es) |
JP (1) | JP6185937B2 (es) |
KR (1) | KR102038948B1 (es) |
CN (1) | CN104271142B (es) |
AU (1) | AU2013225716B2 (es) |
BR (1) | BR112014021653B1 (es) |
CA (1) | CA2866115C (es) |
DK (1) | DK2819682T3 (es) |
HK (1) | HK1205451A1 (es) |
IL (1) | IL234380B (es) |
IN (1) | IN2014DN07420A (es) |
MX (1) | MX351881B (es) |
NZ (1) | NZ629769A (es) |
RU (1) | RU2657535C2 (es) |
SG (1) | SG11201405359YA (es) |
WO (1) | WO2013131040A1 (es) |
ZA (1) | ZA201406373B (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5548121B2 (ja) | 2007-05-14 | 2014-07-16 | リサーチ ファウンデーション オブ ステイト ユニバーシティ オブ ニューヨーク | バイオフィルム中の細菌細胞における生理学的分散応答の誘導 |
MX351881B (es) | 2012-03-01 | 2017-11-01 | Firststring Res Inc | Geles tópicos que contienen péptidos de alfa-conexina c- terminal (act). |
US11246821B2 (en) * | 2016-08-30 | 2022-02-15 | Rohm And Haas Company | Personal care composition |
WO2018151823A1 (en) * | 2017-02-16 | 2018-08-23 | Firststring Research, Inc. | Composition and methods for preventing radiation injury and promoting tissue regeneration |
JP6901801B2 (ja) * | 2017-06-14 | 2021-07-14 | バイオソリューション カンパニー・リミテッドBio Solution Co Ltd | 物質pを含むしわの改善または抗炎症化粧料組成物 |
US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
BR112021004731A2 (pt) * | 2018-09-12 | 2021-09-08 | Firststring Research, Inc. | Formulações de nanopartículas e métodos de uso para peptídeos de terminal-c alfa conexina. |
RU2691647C1 (ru) * | 2018-11-29 | 2019-06-17 | Артем Иванович Трофименко | Средство для профилактики образования патологических кожных рубцов |
US11751056B2 (en) * | 2020-08-31 | 2023-09-05 | Oracle International Corporation | Methods, systems, and computer readable media for 5G user equipment (UE) historical mobility tracking and security screening using mobility patterns |
WO2023212446A1 (en) * | 2022-04-29 | 2023-11-02 | Xequel Bio, Inc. | Compositions and methods for treating complications of viral infections and other respiratory disorders |
CN117582401B (zh) * | 2023-12-07 | 2024-04-26 | 唐宁医药科技(济南)有限公司 | 一种糖尿病足凝胶及其制备方法 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3603444A1 (de) | 1986-02-05 | 1987-08-06 | Thomae Gmbh Dr K | Pharmazeutische zubereitungsformen zur stabilisierung von interferon alpha |
NZ222413A (en) | 1986-11-05 | 1991-06-25 | Ethicon Inc | Compositions containing a polypeptide growth factor and a water-soluble cellulose polymer stabiliser |
US5234809A (en) | 1989-03-23 | 1993-08-10 | Akzo N.V. | Process for isolating nucleic acid |
CA2080538A1 (en) * | 1991-10-21 | 1993-04-22 | Joseph V. Bondi | Lyophilized acidic fibroblast growth factor |
US5401504B1 (en) * | 1993-12-28 | 1998-04-21 | Univ Mississippi Medical Cente | Use of tumeric in wound healing |
ES2498745T3 (es) | 1999-01-27 | 2014-09-25 | Coda Therapeutics, Inc. | Formulaciones que comprenden nucleótidos antisentido para conexinas |
WO2000069896A2 (en) | 1999-05-14 | 2000-11-23 | Arbor Vita Corporation | Molecular interactions in haematopoietic cells |
US7250397B2 (en) | 2000-02-23 | 2007-07-31 | Zealand Pharma A/S | Antiarrhythmic peptides |
WO2002042422A2 (en) | 2000-11-10 | 2002-05-30 | Arbor Vita Corporation | Molecular interactions in hematopoietic cells |
WO2002088370A2 (en) | 2001-04-30 | 2002-11-07 | Protiva Biotherapeutics Inc. | Autogene nucleic acids encoding a secretable rna polymerase |
US6867283B2 (en) | 2001-05-16 | 2005-03-15 | Technion Research & Development Foundation Ltd. | Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells |
US20050053918A1 (en) | 2001-05-16 | 2005-03-10 | Technion Research & Development Foundation Ltd. | Method of identifying peptides capable of binding to MHC molecules, peptides identified thereby and their uses |
US6685971B2 (en) | 2001-06-28 | 2004-02-03 | Rongxiang Xu | Method and composition for repairing and promoting regeneration of mucosal tissue in the gastrointestinal tract |
CN1827766B (zh) | 2001-06-28 | 2010-08-25 | 徐荣祥 | 体外细胞的培养方法 |
EP1443951A4 (en) | 2001-08-03 | 2006-05-03 | Arbor Vita Corp | MOLECULAR INTERACTIONS IN CELLS |
JP2005509621A (ja) | 2001-10-17 | 2005-04-14 | ユニバーシティ オブ ウェールズ カレッジ オブ メディスン | ギャップ結合ならびにedhf |
JP2003238441A (ja) | 2002-02-08 | 2003-08-27 | 英行 ▲高▼野 | 血管新生抑制剤 |
AU2003234613A1 (en) | 2002-05-15 | 2003-12-02 | Seul, Kyung, Hwan | Method of modulating angiogenesis |
IL152573A (en) * | 2002-10-31 | 2009-11-18 | Transpharma Medical Ltd | A system for the transmission through the skin of a medical preparation against vomiting and nausea |
DK1699924T3 (da) | 2003-12-03 | 2019-10-21 | Ocunexus Therapeutics Inc | Connexin 43-målrettede hæmmende forbindelser og fremgangsmåder til anvendelse deraf i behandling af hornhindetraume |
US7786074B2 (en) | 2004-12-21 | 2010-08-31 | MUSC Foundation for Research Development Charleston | Composition and methods for promoting wound healing and tissue regeneration |
CN101151043B (zh) * | 2004-12-21 | 2013-09-04 | 南卡罗来纳州医科大学研究发展基金会 | 促进伤口愈合和组织再生的组合物和方法 |
CA2596412A1 (en) | 2005-02-03 | 2006-12-21 | Coda Therapeutics Limited | Anti-connexin compounds and uses thereof |
CA2612405A1 (en) * | 2005-06-17 | 2006-12-28 | Regenerx Biopharmaceuticals, Inc. | Lkktet and/or lkktnt compositions and methods for treating or preventing tissue deterioration, injury or damage |
CN101198346A (zh) * | 2005-06-17 | 2008-06-11 | 雷金纳克斯生物制药公司 | Lkktet和/或lkktnt肽组合物及方法 |
WO2007044487A1 (en) * | 2005-10-11 | 2007-04-19 | Dfb Pharmaceuticals, Inc. | Surfactant-free dispersions, compositions, and use in topical formulations |
GB0709513D0 (en) * | 2007-05-17 | 2007-06-27 | Helperby Therapeutics Ltd | Topical formulations |
WO2008060622A2 (en) | 2006-11-15 | 2008-05-22 | Coda Therapeutics, Inc. | Improved methods and compositions for wound healing |
EP2543378A1 (en) | 2006-12-11 | 2013-01-09 | Coda Therapeutics, INC. | Anticonnexin polynucleotides as impaired wound healing compositions |
US20080299228A1 (en) * | 2007-05-29 | 2008-12-04 | Alan Gerald Harris | Topical compositions comprising a macromolecule and methods of using same |
US20110130345A1 (en) | 2007-06-21 | 2011-06-02 | Baerbel Rohrer | Alpha connexin c-terminal (act) peptides for treating age-related macular degeneration |
CA2592285C (en) | 2007-06-28 | 2019-10-01 | Musc Foundation For Research Development | Compositions comprising connexin polypeptides and methods for promoting wound healing and tissue regeneration using connexin polypeptides |
CN102105492A (zh) * | 2007-12-11 | 2011-06-22 | 科达治疗公司 | 受损伤口愈合的组合物和治疗 |
US20100279921A1 (en) | 2007-12-11 | 2010-11-04 | Coda Therapeutics, Inc. | Impaired wound healing compositions and treatments |
JP2011507856A (ja) | 2007-12-21 | 2011-03-10 | コーダ セラピューティクス, インコーポレイテッド | 整形外科状態の治療のための抗コネキシンポリヌクレオチド、ペプチド、または抗体の使用 |
EP2252689A2 (en) | 2007-12-21 | 2010-11-24 | Coda Therapeutics, Inc. | Use of anti-connexin polynucleotides for the treatment of surgical adhesions |
AU2008343842A1 (en) | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Use of anti-connexin peptides, alone or in combination with anti-connexin polynucleotides, for the treatment of orthopedic conditions |
US20110130710A1 (en) | 2007-12-21 | 2011-06-02 | David Lawrence Becker | Treatment of abnormal or excessive scars |
CA2710387A1 (en) | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Treatment of fibrotic conditions |
JP2011507599A (ja) * | 2007-12-21 | 2011-03-10 | コーダ セラピューティクス, インコーポレイテッド | 改良医療デバイス |
AU2008343841A1 (en) | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Use of inhibitors of connexin43 for treatment of fibrotic conditions |
AU2008343839A1 (en) | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Use of anti-connexin peptides, alone or in combination with anti-connexin polynucleotides, for the treatment of surgical adhesions |
WO2009085274A2 (en) | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Use of anti-connexin polynucleotides and peptides for the treatment ofabnormal or excessive scars |
CA2711635A1 (en) * | 2008-01-07 | 2009-08-06 | Coda Therapeutics, Inc. | Wound healing compositions and treatments |
JP2011524345A (ja) | 2008-06-04 | 2011-09-01 | コーダ セラピューティクス, インコーポレイテッド | ギャップジャンクション調節化合物を用いる疼痛の治療 |
MX351881B (es) | 2012-03-01 | 2017-11-01 | Firststring Res Inc | Geles tópicos que contienen péptidos de alfa-conexina c- terminal (act). |
-
2013
- 2013-03-01 MX MX2014010501A patent/MX351881B/es active IP Right Grant
- 2013-03-01 CN CN201380023492.XA patent/CN104271142B/zh active Active
- 2013-03-01 AU AU2013225716A patent/AU2013225716B2/en active Active
- 2013-03-01 JP JP2014560104A patent/JP6185937B2/ja active Active
- 2013-03-01 KR KR1020147027397A patent/KR102038948B1/ko active IP Right Grant
- 2013-03-01 DK DK13755720.3T patent/DK2819682T3/en active
- 2013-03-01 WO PCT/US2013/028727 patent/WO2013131040A1/en active Application Filing
- 2013-03-01 CA CA2866115A patent/CA2866115C/en active Active
- 2013-03-01 SG SG11201405359YA patent/SG11201405359YA/en unknown
- 2013-03-01 BR BR112014021653-3A patent/BR112014021653B1/pt active IP Right Grant
- 2013-03-01 NZ NZ629769A patent/NZ629769A/en unknown
- 2013-03-01 RU RU2014139668A patent/RU2657535C2/ru active
- 2013-03-01 EP EP13755720.3A patent/EP2819682B1/en active Active
- 2013-03-15 US US13/815,723 patent/US8846605B2/en active Active
-
2014
- 2014-07-25 US US14/341,406 patent/US9161984B2/en active Active
- 2014-08-29 ZA ZA2014/06373A patent/ZA201406373B/en unknown
- 2014-08-31 IL IL234380A patent/IL234380B/en active IP Right Grant
- 2014-09-03 IN IN7420DEN2014 patent/IN2014DN07420A/en unknown
-
2015
- 2015-06-19 HK HK15105846.8A patent/HK1205451A1/xx unknown
- 2015-09-09 US US14/848,916 patent/US10632173B2/en active Active
-
2020
- 2020-04-27 US US16/859,075 patent/US11524049B2/en active Active
-
2022
- 2022-10-06 US US17/938,624 patent/US20230263857A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2014010501A (es) | Geles tópicos que contienen péptidos de alfa-conexina c- terminal (act). | |
BR112012029975A2 (pt) | peptídeo como medicamento, em particular para o tratamento do câncer. | |
BR112016029848A2 (pt) | proteínas de fusão mic-1 e utilizações das mesmas | |
MY161773A (en) | Amylin analogues and pharmaceutical compositions thereof | |
MY171146A (en) | Compositions of glp-1 peptides and preparation thereof | |
PH12014500922A1 (en) | Insulinotropic peptide derivative wherein its n-terminal amino acid is modified | |
MX2016001971A (es) | Composiciones farmaceuticas parenterales acuosas estables de peptidos insulinotropicos. | |
CY1119036T1 (el) | Νεοι αγωνιστες του υποδοχεα τυπου 2 της αγγειοτενσινης (ατ2) και χρησεις τους | |
WO2018067217A3 (en) | COMPOSITIONS COMPRISING SHORT PEPTIDES DERIVED FROM PEDF AND USES THEREOF | |
EP3533461A3 (en) | Prame derived peptides and immunogenic compositions comprising these | |
WO2015183963A3 (en) | Therapeutic compositions including redox-active parabenzoquinones and uses thereof | |
BR112018072034A2 (pt) | compostos mic-1 e usos dos mesmos | |
IN2014DN03213A (es) | ||
EA201500061A1 (ru) | Фармацевтическая композиция для терапии легочной формы высотной болезни, вызванной кислородным голоданием и пониженным атмосферным давлением | |
MX2019006515A (es) | Composiciones que comprenden peptido wkdeagkplvk. | |
MX338156B (es) | Formulaciones topicas de tipo suspension que comprenden depsipeptido ciclico. | |
IN2014DN06920A (es) | ||
ZA200807027B (en) | Peptides and peptide derivatives, the production thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition | |
WO2017093810A3 (en) | Composition for intraoral delivery of biologically active peptides and proteins | |
GEP201606514B (en) | Apoptosis inhibitors and usage thereof | |
BR112017014737A2 (pt) | formulação de peptídeos inibidores de mk2 | |
MX2011007462A (es) | Composiciones que contienen acido hialuronico para el tratamiento de heridas, cicatrices, formacion de dahesiones postquirurgicas. | |
MX2013003545A (es) | Peptidos del veneno de escorpion rhopalorus junceus y composicion farmaceutica. | |
EP4014987A3 (en) | Cyclic peptide, and medicine, external preparation and cosmetic each containing said cyclic peptide | |
WO2014039074A3 (en) | Therapeutic compositions and related methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |